Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Interlude Biopharma Co. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The current workload is handled by 1 distinct examiner and 1 distinct art unit, which indicates a focused prosecution stage for the company. With this pending action, the company's current patent office interactions are concentrated on a single application. This concentration means the company's immediate intellectual property goals are tied to the outcome of this matter.
The busiest examiner for the company is MIKNIS, ZACHARY J. This examiner is managing 1 pending office action, which represents the full volume of pending actions for the organization. Since the prosecution involves 1 distinct examiner and 1 distinct art unit, the company can tailor its response to the specific technical and procedural preferences of this examiner. The assigned art unit is the primary focus of the company's current prosecution efforts, as the 1 pending action is subject to the specific standards of that administrative silo.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MIKNIS, ZACHARY J | 1 | 68.6% | +32.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17996228 | LARAZOTIDE DERIVATIVES COMPRISING D-AMINO ACIDS | MIKNIS, ZACHARY J | 53d overdue |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17996228 | LARAZOTIDE DERIVATIVES COMPRISING D-AMINO ACIDS | MIKNIS, ZACHARY J | 1658 | §103 | Final Rejection | 53d overdue | Pending | Oct 14, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial